Literature DB >> 10618607

Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection.

S S Mudan1, K C Conlon, J M Woodruff, J J Lewis, M F Brennan.   

Abstract

BACKGROUND: Gastrointestinal sarcomas are rare stromal tumors and most are classifiable as malignant gastrointestinal stromal tumors. They have a high propensity for intraabdominal recurrence. It is unclear whether there is a survival advantage from reoperation for recurrent disease or if surgery should be confined to symptom relief. The authors have attempted to identify features that may allow the selection of patients most likely to benefit from reoperation.
METHODS: Retrospective univariate and multivariate analyses of 60 patients with recurrent gastrointestinal sarcoma, accrued from a prospective data base between July 1982 and September 1995, were performed.
RESULTS: Initial recurrence was evident by a median of 20 months from primary resection. Most patients (85%) had an initial symptomatic recurrence. Local recurrence was seen in 76% of patients, but in half of these synchronous hepatic metastases were present. None had disease outside of the abdomen. Complete resection of recurrent disease was possible in only one-third of cases. Median survival after surgery for recurrence was 15 months, but was longest for patients whose recurrence took the form of liver metastases in the absence of disease elsewhere. In multivariate analysis of post-recurrence survival, the only significant determinant of survival was the length of the disease free interval between the initial operation and recurrence.
CONCLUSIONS: Survival following recurrence of a gastrointestinal sarcoma is largely determined by the tumor biology, one manifestation of which is the disease free interval. Except for patients with a long disease free interval, surgery should be reserved largely for symptom control. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10618607     DOI: 10.1002/(sici)1097-0142(20000101)88:1<66::aid-cncr10>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

Review 1.  Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST).

Authors:  Marcovalerio Melis; Eugene A Choi; Robert Anders; Peter Christiansen; Alessandro Fichera
Journal:  Int J Colorectal Dis       Date:  2006-04-26       Impact factor: 2.571

2.  A rare case of huge gastrointestinal stromal tumor (GIST) of the stomach extending into the posterior mediastinum.

Authors:  Hideki Machishi; Yoshikatsu Okada; Moritaka Nagai; Naoya Noda; Tomohide Hori; Takashi Shimono; Toshio Fukudome
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

3.  Surgical margin status and prognosis of gastrointestinal stromal tumor.

Authors:  António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

Review 4.  Gastrointestinal stromal tumors.

Authors:  Maureen J O'Sullivan
Journal:  Pediatr Surg Int       Date:  2009-10       Impact factor: 1.827

Review 5.  Gastrointestinal stromal tumours: advances in surgical and pharmacological management options.

Authors:  Amitabh Thacoor
Journal:  J Gastrointest Oncol       Date:  2018-06

Review 6.  Gastrointestinal stromal tumour in Ibadan, Nigeria: a case report and review of current treatment.

Authors:  O O Afuwape; D O Irabor; J K Ladipo
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

7.  Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

Authors:  Ferdinando C M Cananzi; Bruno Lorenzi; Ajay Belgaumkar; Charlotte Benson; Ian Judson; Satvinder Mudan
Journal:  Langenbecks Arch Surg       Date:  2014-01-12       Impact factor: 3.445

8.  Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.

Authors:  Tatsuo Kanda; Takashi Ishikawa; Shin-Ichi Kosugi; Kyo Ueki; Tetsuya Naito; Toshifumi Wakai; Seiichi Hirota
Journal:  Int J Clin Oncol       Date:  2015-09-19       Impact factor: 3.402

9.  Gastrointestinal stromal tumors (GIST): a prospective evaluation of risk factors and prognostic scores.

Authors:  Juan Manuel Sanchez Hidalgo; Sebastian Rufian Peña; Ruben Ciria Bru; Alvaro Naranjo Torres; Cristobal Muñoz Casares; Juan Ruiz Rabelo; Javier Briceño Delgado
Journal:  J Gastrointest Cancer       Date:  2010-03

10.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis.

Authors:  Reese W Randle; Katrina R Swett; Perry Shen; John H Stewart; Edward A Levine; Konstantinos I Votanopoulos
Journal:  Am Surg       Date:  2013-06       Impact factor: 0.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.